Search

Your search keyword '"Ozge Ozer Kaya"' showing total 2 results
Start Over Author "Ozge Ozer Kaya" Journal molecular genetics & genomic medicine
2 results on '"Ozge Ozer Kaya"'

1. Targeted fetal cell‐free DNA screening for aneuploidies in 4,594 pregnancies: Single center study

Author

Altug Koc, Ozge Ozer Kaya, Berk Ozyilmaz, Yasar B. Kutbay, Ozgur Kirbiyik, Taha R. Ozdemir, Kadri M. Erdogan, Merve Saka Guvenc, Deniz C. Oztekin, Mehmet Ozeren, Halil G. Pala, Atalay Ekin, Cenk Gezer, Alkim G. Sahingoz Yildirim, Bahar Konuralp Atakul, Secil Kurtulmus, Ugur Turhan, and Cuneyt E. Taner

Subjects
cfDNA screening, NIPS, NIPT, Genetics, QH426-470
Abstract

Abstract Background Next‐generation sequencing (NGS) and discovery of fetal cell‐free DNA (cfDNA) in the maternal circulation render possible prenatal screening for trisomy 21 (Down syndrome), trisomy 18, trisomy 13, and sex chromosome aneuploidies. The approach is called “fetal cfDNA screening” and in contrast to noninvasive conventional serum screening, it provides the identification of 98%–99% of fetuses with Down syndrome. Methods Retrospective analysis of targeted noninvasive prenatal testing (NIPT) (Clarigo Test) pregnancies with moderate risk, which we have reported between 2016 and 2018 years is presented. Two separate laboratory workflows and NGS platforms are used for the same targeted NIPT analysis. Results In total, 4,594 pregnant women were investigated. Initial 3,594 cases are studied by MiSeq platform, the last 1,000 cases by NextSeq. Failure rate for MiSeq platform is 10.9% and for NextSeq is 8.7%. Automatically reported cases constitute 75% of the MiSeq group and 87% of the NextSeq group. Conclusions Targeted NIPT results suggest that MiSeq platform could be used for NIPT which would be an essential option particularly for laboratories with low sample flow. And, the NextSeq platform has easier wet lab process and also increased success rate in automatic reporting which is suitable for centers with high number of NIPT cases.

Published
2019
Full Text
View/download PDF

2. Targeted fetal cell‐free DNA screening for aneuploidies in 4,594 pregnancies: Single center study

Author

Alkim Gulsah Sahingoz Yildirim, Cenk Gezer, Kadri Murat Erdoğan, Bahar Konuralp Atakul, Ugur Turhan, Yasar B. Kutbay, Atalay Ekin, Berk Ozyilmaz, Taha Reşid Özdemir, Ozgur Kirbiyik, Merve Saka Guvenc, Cüneyt Eftal Taner, Mehmet Özeren, Halil Gürsoy Pala, Seçil Kurtulmuş, Deniz Öztekin, Altuğ Koç, and Ozge Ozer Kaya

Subjects
Adult, 0301 basic medicine, Down syndrome, medicine.medical_specialty, Adolescent, Trisomy 13 Syndrome, lcsh:QH426-470, Genetic Counseling, Gestational Age, 030105 genetics & heredity, Single Center, Free dna, Young Adult, 03 medical and health sciences, Fetus, Fetal cell, Pregnancy, Prenatal Diagnosis, Genetics, medicine, Retrospective analysis, Humans, Genetic Testing, Molecular Biology, Genetics (clinical), Retrospective Studies, business.industry, Obstetrics, High-Throughput Nucleotide Sequencing, Sequence Analysis, DNA, Original Articles, cfDNA screening, Middle Aged, Aneuploidy, medicine.disease, NIPS, lcsh:Genetics, 030104 developmental biology, Prenatal screening, Female, Original Article, Down Syndrome, Serum screening, Trisomy, business, Cell-Free Nucleic Acids, Trisomy 18 Syndrome, NIPT
Abstract

Background Next‐generation sequencing (NGS) and discovery of fetal cell‐free DNA (cfDNA) in the maternal circulation render possible prenatal screening for trisomy 21 (Down syndrome), trisomy 18, trisomy 13, and sex chromosome aneuploidies. The approach is called “fetal cfDNA screening” and in contrast to noninvasive conventional serum screening, it provides the identification of 98%–99% of fetuses with Down syndrome. Methods Retrospective analysis of targeted noninvasive prenatal testing (NIPT) (Clarigo Test) pregnancies with moderate risk, which we have reported between 2016 and 2018 years is presented. Two separate laboratory workflows and NGS platforms are used for the same targeted NIPT analysis. Results In total, 4,594 pregnant women were investigated. Initial 3,594 cases are studied by MiSeq platform, the last 1,000 cases by NextSeq. Failure rate for MiSeq platform is 10.9% and for NextSeq is 8.7%. Automatically reported cases constitute 75% of the MiSeq group and 87% of the NextSeq group. Conclusions Targeted NIPT results suggest that MiSeq platform could be used for NIPT which would be an essential option particularly for laboratories with low sample flow. And, the NextSeq platform has easier wet lab process and also increased success rate in automatic reporting which is suitable for centers with high number of NIPT cases.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results